AnorMED to present data showing Mozobil's potential in stem cell transplantation for cancer patients

New York, Nov. 15 - AnorMED Inc. said studies to be described at an upcoming conference support the potential of its Mozobil drug to help stem cell mobilization for cancer patients undergoing transplantation.

The data, in 12 clinical and preclinical abstracts, will be presented at the American Society of Hematology annual meeting in Atlanta from Dec. 10-13.

Stem cell transplantation is a standard medical procedure used to restore the immune system of patients who have had chemotherapy to treat cancers, such as multiple myeloma and non-Hodgkin's lymphoma, among others, AnorMED noted. The strongest predictor of success in transplantation, measured by the rapid and durable recovery of a patient's immune system, is the number of stem cells available for transplant.

Mobozil has been shown to mobilize stem cells, causing them to move out of the bone marrow and into the circulating blood, the company said. About 45,000 stem cell transplantations are performed each year around the world. Up to 65% of transplant patients have poor or sub-optimal mobilization of stem cells from the bone marrow into the bloodstream using standard mobilization treatments.

AnorMED, a Vancouver, B.C., biopharmaceutical company, is evaluating Mozobil in two phase 3 studies in the United States. It plans to complete recruitment and three-month follow up by the end of 2006.

AnorMED also has a phase 2 program for the drug in transplant centers in the United States, Canada and the European Union.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.